Detection and Identification of Pathogens in Emerging Infectious Diseases

Emerging infectious disease pathogen detection encompasses laboratory techniques designed for the rapid identification, characterization, and surveillance of novel pathogens such as SARS-CoV-2, MERS-CoV, avian influenza viruses, and other newly identified microorganisms. Accurate and timely pathogen detection is essential for outbreak response, public health surveillance, vaccine development, and clinical management. This article provides a comprehensive technical overview of sample types, testing items, analytical methods, biosafety considerations, and applications of emerging infectious disease pathogen detection.

Technical Overview

Emerging infectious diseases (EIDs) are diseases caused by newly identified pathogens or known pathogens that have expanded in geographic range, host range, or transmissibility. Pathogen detection for EIDs presents unique analytical challenges because the etiological agent may be unknown at the time of sample collection, reference materials may be scarce, and validated diagnostic assays may not yet exist. Modern EID pathogen detection relies on a multi-layered approach combining molecular diagnostics, immunological methods, culture-based techniques, and unbiased genomic discovery platforms.

The detection workflow for emerging pathogens typically follows a cascade: initial screening with broad-spectrum molecular assays (such as pan-coronavirus or pan-influenza PCR panels), confirmatory testing with pathogen-specific real-time PCR, genomic characterization through next-generation sequencing (NGS), and isolation of the infectious agent under appropriate bios containment conditions. International guidance from organizations such as the World Health Organization (WHO), ISO (including ISO 15189 for medical laboratory quality management), and CLSI provides frameworks for assay validation, quality assurance, and biosafety in high-consequence pathogen testing.

Biosafety is a critical component of EID pathogen detection. Laboratory manipulations involving suspected high-consequence pathogens must follow risk assessments aligned with the WHO Laboratory Biosafety Manual and relevant national regulations. Many molecular procedures (nucleic acid extraction, PCR setup) can be performed on chemically inactivated samples under BSL-2 conditions, while virus isolation and culture of certain novel agents may require BSL-3 or BSL-4 containment.

Testing Samples

Respiratory Specimens

Respiratory samples are the primary specimen type for detecting airborne and droplet-transmitted emerging pathogens, including novel coronaviruses, influenza A(H5N1, H7N9), and zoonotic paramyxoviruses. Appropriate specimens include nasopharyngeal and oropharyngeal swabs, sputum, bronchoalveolar lavage fluid (BALF), tracheal aspirates, and nasopharyngeal aspirates. BALF generally provides the highest viral load for lower respiratory tract infections and is particularly valuable for novel pathogen discovery.

Blood and Serum Specimens

Whole blood (in EDTA anticoagulant) is used for molecular detection of pathogens causing viremia or systemic infection, such as novel arboviruses (Zika virus, Crimean-Congo hemorrhagic fever virus) and hemorrhagic fever viruses. Serum is the preferred specimen for serological testing, including IgM/IgG antibody detection, plaque reduction neutralization tests (PRNT), and antigen-capture ELISA. Paired acute and convalescent sera are useful for demonstrating seroconversion in novel pathogen investigations.

Fecal and Rectal Swab Specimens

Stool samples and rectal swabs are relevant for emerging enteric pathogens, such as novel enteroviruses, rotavirus variants, and coronaviruses with fecal-oral shedding patterns (including SARS-CoV-2 gastrointestinal shedding). Environmental sewage surveillance has also become a powerful tool for community-level monitoring of emerging pathogen circulation and variant emergence.

Other Clinical and Environmental Specimens

Additional sample types include urine (for certain arboviruses and hemorrhagic fever viruses), cerebrospinal fluid (for neuroinvasive pathogens such as enterovirus D68 and Zika virus), tissue biopsies and autopsy materials (for severe or fatal cases of unknown etiology), ocular and conjunctival swabs, vesicle fluid, and environmental samples from suspected zoonotic source investigations, including animal tissues, wildlife specimens, and market environmental swabs.

Sample Collection, Transport, and Storage Requirements

• Respiratory and other clinical swabs should be placed in viral transport medium (VTM) containing protein stabilizers and antimicrobial agents.
• Samples must be transported at 2–8°C when testing occurs within 48–72 hours; for longer delays, storage at −70°C or below is recommended.
• Repeated freeze-thaw cycles should be avoided to preserve nucleic acid integrity and viral viability.
• Triple containment packaging and compliance with national and international regulations for transport of infectious substances (UN 3373 Category B or UN 2814 Category A) are mandatory.
• Chain-of-custody documentation and proper sample labeling are essential for traceability in outbreak investigations.

Testing Items

Testing for emerging infectious disease pathogens encompasses multiple analyte categories depending on the stage of the outbreak investigation and the biological characteristics of the suspected agent.

• Nucleic acid detection — qualitative and quantitative real-time PCR (qPCR) and RT-PCR assays targeting pathogen-specific genes, including dual-target assays (e.g., ORF1ab and N gene for SARS-CoV-2) to reduce false-negative results from mutations.
• Multiplex molecular panels — syndromic panels covering respiratory pathogens ( FilmArray-type respiratory panels), gastrointestinal panels, and meningitis/encephalitis panels that include emerging pathogen targets alongside common agents.
• Pathogen discovery and unbiased sequencing — metagenomic next-generation sequencing (mNGS) for identification of novel or unexpected pathogens directly from clinical specimens without prior sequence knowledge.
• Whole-genome sequencing and genomic characterization — full viral genomes or bacterial whole genomes for variant identification, phylogenetic analysis, mutation surveillance, and origin tracing.
• Antigen detection — rapid immunochromatographic antigen tests and quantitative antigen-capture ELISAs for point-of-care and high-throughput screening applications.
• Antibody detection — total antibody, IgM, and IgG assays (ELISA, chemiluminescence, lateral flow) for serodiagnosis, seroprevalence studies, and immune response evaluation.
• Virus isolation and culture — propagation of viable virus in cell culture systems or animal models under appropriate biocontainment, confirming replication-competent infection and providing isolates for research.
• Phenotypic and genetic characterization — antiviral resistance testing, susceptibility to disinfectants, environmental stability, and in vitro drug susceptibility for bacterial or parasitic emerging agents.
• Digital PCR quantification — absolute quantification of pathogen load with high sensitivity, useful for low-titer samples, wastewater surveillance, and reference material development.

Testing Methods

Real-Time Fluorescent PCR and RT-PCR

Real-time quantitative PCR (qPCR) and reverse-transcription real-time PCR (RT-PCR) are the gold-standard molecular methods for confirmatory detection of emerging pathogens with known sequences. Assays targeting conserved genomic regions (such as the E and RdRp genes for coronaviruses, or the M gene for influenza) are designed following WHO or CDC-published protocols. Analytical validation includes determining the limit of detection (LoD), analytical specificity against related pathogens and normal flora, PCR efficiency (90–110%), and inclusivity against circulating genetic variants. Internal amplification controls detect PCR inhibition, while negative and positive controls in each run guard against contamination.

Metagenomic Next-Generation Sequencing (mNGS)

Metagenomic NGS is an unbiased, hypothesis-free approach that sequences all nucleic acids present in a clinical or environmental sample. It has been instrumental in discovering and characterizing novel pathogens, including SARS-CoV-2, novel bunyaviruses, and unclassified viral agents. The mNGS workflow includes nucleic acid extraction with host nucleic acid depletion (using saponin or DNase/capture methods), library preparation, deep sequencing, bioinformatic classification against reference databases, and statistical interpretation. Host DNA/RNA depletion is critical for respiratory and blood specimens where human nucleic acid can constitute over 99% of reads.

Whole-Genome Sequencing and Targeted Amplicon Sequencing

For pathogens with established reference genomes, targeted amplicon sequencing (such as the ARTIC tiled-amplicon approach used for SARS-CoV-2) enables rapid, cost-effective genomic surveillance. Hybrid capture and bait-based enrichment methods are used for low-titer samples. Generated genomes support lineage assignment (e.g., Pango nomenclature for SARS-CoV-2), clade classification, and identification of mutations of concern affecting transmissibility, antigenicity, or therapeutic susceptibility.

Immunological and Serological Methods

Serological approaches include indirect and capture ELISA, immunofluorescence assay (IFA), western blot, chemiluminescent microparticle immunoassay, and lateral-flow rapid tests for antigen or antibody detection. Neutralization assays (micro-neutralization, PRNT, and pseudovirus-based neutralization) measure functional antibody responses and are essential for vaccine immunogenicity evaluation and variant immune-escape assessment. Serological cross-reactivity among antigenically related viruses (e.g., within the Flavivirus genus) requires careful interpretation and often confirmatory testing.

Pathogen Culture and Isolation

Virus isolation is performed in permissive cell lines (Vero E6, LLC-MK2, MDCK and others depending on the virus family), embryonated eggs, or susceptible animal models. Cytopathic effect (CPE), hemagglutination, and immunofluorescent confirmation verify isolation success. Bacterial emerging pathogens are cultured on selective and enriched media, followed by biochemical identification, MALDI-TOF mass spectrometry, and antimicrobial susceptibility testing. Culture-based work with high-consequence pathogens requires elevated biocontainment and institutional approval.

Additional and Supporting Techniques

• Digital PCR (dPCR) — partition-based absolute quantification with enhanced sensitivity and tolerance to inhibitors, suitable for reference measurement and low-copy detection.
• Isothermal amplification — RT-LAMP and RPA assays enabling rapid, equipment-light molecular detection suitable for field deployment and point-of-care testing.
• CRISPR-based diagnostics — SHERLOCK and DETECTR platforms combining isothermal amplification with CRISPR-Cas collateral cleavage for highly specific, visually readable pathogen detection.
• Mass spectrometry — MALDI-TOF MS for bacterial identification and advanced proteomic methods for viral protein characterization.
• Electron microscopy — negative-stain and cryo-electron microscopy providing morphological evidence of viral particles in early pathogen characterization.
• Environmental surveillance — wastewater epidemiology using concentrated sewage samples to monitor community pathogen burden and early variant emergence.

Quality Assurance and Standards

Laboratories performing EID pathogen detection should operate under a quality management framework compliant with ISO 15189 (medical laboratories) or ISO/IEC 17025 (testing laboratories). Method validation follows ISO 15193/15194/15195 principles for in vitro diagnostic procedures. External quality assessment (EQA) participation, proficiency testing panels distributed by national reference laboratories and WHO collaborating centers, and documented contamination-control procedures (unidirectional workflow, separate pre- and post-amplification areas, UDG/dUTP carryover prevention) are fundamental to result reliability. Certified reference materials and internationally distributed panel samples support assay harmonization across laboratories.

Applications

• Outbreak investigation and pathogen discovery — identifying the etiological agent of unexplained pneumonia, febrile illness clusters, or encephalitis syndromes of unknown origin.
• Clinical diagnosis and patient management — confirming infection in suspected cases, monitoring viral clearance, guiding antiviral therapy, and assessing disease severity correlation with pathogen load.
• Public health surveillance — case-finding, contact tracing support, sentinel surveillance, wastewater monitoring, and early warning of community transmission.
• Genomic surveillance and variant tracking — monitoring the emergence of variants with altered transmissibility, virulence, or antigenic properties, informing vaccine composition updates.
• Zoonotic source investigation — tracing animal reservoirs and intermediate hosts through wildlife sampling, livestock monitoring, and environmental surveillance at potential spillover interfaces.
• Vaccine and therapeutic development — providing characterized isolates, genomic sequences, and neutralization assay support for countermeasure research and evaluation.
• Border health and travel screening — supporting entry screening, pre-departure testing requirements, and international health regulation (IHR) reporting.
• Research and preparedness — establishing diagnostic capacity, developing prototype assays, and conducting serosurveys to determine population immunity against emerging threats.

FAQ

What is the difference between metagenomic sequencing and targeted PCR testing for emerging pathogens?

Targeted PCR (including multiplex panels) is fast, inexpensive, and highly sensitive but requires prior knowledge of the pathogen's sequence. Metagenomic sequencing (mNGS) is unbiased and can detect unexpected or completely novel pathogens without any pre-existing assay, making it the primary tool for discovery-phase investigation of unexplained illness. However, mNGS is more expensive, slower, and may be less sensitive than PCR for known low-titer targets; the two approaches are complementary rather than interchangeable.

How long does emerging pathogen detection typically take?

Rapid antigen tests provide results in 15–30 minutes; real-time PCR results are typically available within 2–4 hours of sample receipt; targeted amplicon sequencing can produce genomic data within 24–48 hours; full mNGS workflows, including extraction, library preparation, sequencing, and bioinformatics, generally require 24–72 hours depending on laboratory capacity. Virus isolation may require several days to weeks, depending on the pathogen's growth characteristics.

What biosafety level is required for testing emerging pathogens?

The required containment level depends on the suspected pathogen and the procedure. Molecular testing on chemically inactivated specimens (heat-inactivated or lysis buffer-treated) can generally be performed at BSL-2 following a thorough risk assessment. Propagation and culture of high-consequence pathogens, manipulation of concentrated virus stocks, and procedures that may generate aerosols of viable agent typically require BSL-3 or BSL-4 facilities, subject to national regulatory approval and WHO Laboratory Biosafety Manual guidance.

Why do false-negative molecular results occur in emerging pathogen infections?

False negatives can result from low viral load due to early or late sampling, improper specimen type for the disease stage, collection technique errors, degradation during transport, PCR inhibitors in the sample, or sequence variation in primer/probe binding sites of evolving variants. Mitigation strategies include collecting appropriate specimen types at optimal disease stages, using dual-gene target assays, incorporating internal controls, and confirming negative results with repeat testing or an orthogonal method when clinical suspicion remains high.

How are newly developed assays validated when a pathogen is completely novel?

When authentic pathogen material is limited, laboratories use synthetic nucleic acid controls (plasmids, transcribed RNA, synthetic RNA standards) and inactivated cultured virus for initial analytical performance evaluation. Inclusivity is assessed in silico against all available genome sequences, and specificity is challenged against related pathogens and commensal organisms. As the outbreak progresses and more clinical material becomes available, clinical sensitivity and specificity are established using confirmed positive and negative patient panels, followed by external quality assessment distribution and inter-laboratory comparison to ensure harmonized performance.

What is the role of serological testing compared to molecular testing?

Molecular testing identifies active infection and is the primary diagnostic tool during acute illness. Serology detects the host immune response and is most valuable for retrospective diagnosis, seroprevalence surveys, determining the extent of past community transmission, evaluating vaccine-induced immunity, and confirming infection in PCR-negative patients who present late in illness. Cross-reactivity with antigenically related viruses is a key limitation that requires confirmatory testing such as neutralization assays when specificity is critical.

Can wastewater surveillance detect emerging pathogens before clinical cases are identified?

Yes. Wastewater-based epidemiology can detect pathogen nucleic acid shed into sewage before symptomatic cases accumulate, providing an early warning signal of community transmission. It has been successfully applied to poliovirus detection, SARS-CoV-2 variant monitoring, and surveillance for other enteric and respiratory pathogens. Sensitivity depends on sampling frequency, shedding characteristics, catchment population size, and the limit of detection of the concentration and analytical methods used.